Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models

Dysregulation of hepatic lipid and cholesterol metabolism is a significant contributor to cardiometabolic health, resulting in excessive liver lipid accumulation and ultimately non-alcoholic steatohepatitis (NASH). Therapeutic activators of the AMP-Activated Protein Kinase (AMPK) have been proposed...

詳細記述

書誌詳細

主要な著者:	Ryan M. Esquejo, Christopher T. Salatto, Jake Delmore, Bina Albuquerque, Allan Reyes, Yuji Shi, Rob Moccia, Emily Cokorinos, Matthew Peloquin, Mara Monetti, Jason Barricklow, Eliza Bollinger, Brennan K. Smith, Emily A. Day, Chuong Nguyen, Kieran F. Geoghegan, John M. Kreeger, Alan Opsahl, Jessica Ward, Amit S. Kalgutkar, David Tess, Lynne Butler, Norimitsu Shirai, Timothy F. Osborne, Gregory R. Steinberg, Morris J. Birnbaum, Kimberly O. Cameron, Russell A. Miller
フォーマット:	Artigo
言語:	Inglês
出版事項:	Elsevier 2018-05-01
シリーズ:	EBioMedicine
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S2352396418301373
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!